Alps Global, a fully-integrated biotechnology research, medical and wellness services company, agreed to go public via SPAC merger with Globalink Investment, a publicly traded special purpose acquisition company, in a $1.6bn deal. “We are thrilled to announce the entry into the Merger Agreement. We are excited with the opportunities that Alps could offer and we strongly believe in the tremendous opportunity in the life sciences industry,” Say Leong Lim, Globalink CEO.